309 related articles for article (PubMed ID: 29673834)
1. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
2. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
4. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
[TBL] [Abstract][Full Text] [Related]
5. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
6. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
7. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
[TBL] [Abstract][Full Text] [Related]
8. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
9. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U
J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412
[TBL] [Abstract][Full Text] [Related]
11. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.
van Driel C; de Bock GH; Schroevers MJ; Mourits MJ
BJOG; 2019 Feb; 126(3):402-411. PubMed ID: 30222235
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
[TBL] [Abstract][Full Text] [Related]
13. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
14. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
15. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
[TBL] [Abstract][Full Text] [Related]
16. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
17. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
18. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
[TBL] [Abstract][Full Text] [Related]
19. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
20. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.
Benshushan A; Rojansky N; Chaviv M; Arbel-Alon S; Benmeir A; Imbar T; Brzezinski A
Climacteric; 2009 Oct; 12(5):404-9. PubMed ID: 19479488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
